NEW YORK (GenomeWeb News) – 23andMe has named Andy Page to its board of directors. He currently serves as president of Gilt Group. Previously he served as chief operating and financial officer at PlayPhone; chief financial officer and senior vice president of business strategy at StubHub; and has held senior executive positions at Panasas, ONI Systems, and Robertson Stephens & Company.
Pressure Biosciences has trimmed the number of members of its board of directors from eight to five, after five of its members resigned and two new members were named to the board.
The resigning members include Calvin Saravis, Donald Payne, Alan Rosenson, Alan Goldberg, and Gregory Freitag, and the two new members are Vito Mangiardi and Kevin Pollack.
Mangiardi most recently served as COO and deputy director of operations and production for the Joint Genome Institute and has worked for Bio-Rad Laboratories, Baxter Travenol, Quintiles Transnational, and he was president and CEO of Diagnostics Laboratories. Pollack is managing director at Paragon Capital and is president of Short Hills Capital.
French diagnostics developer Theradiag said this week that Gérard Tobelem has been appointed chairman of its board of directors, taking over the spot from Philippe Pouletty. Pierre Morgon and Jean-Paul Prieels also have joined the board. Pouletty will continue to serve on the board, Theradiag said.
Tobelem formerly was chief executive of the French national blood transfusion service, and he has worked as a consultant for R&D companies for several years. Prieels was senior VP of R&D at GlaxoSmithKline Biological's R&D Division, where he worked for over 20 years, and Morgon has had a 26-year career at pharmaceutical companies such as Sanofi-Pasteur, where he currently is VP of franchise and global marketing strategy.
BG Medicine said this week that Bill Densel has joined the company as general manager of its CardioScore business, which offers a diagnostic blood test for identifying individuals at high risk for major near-term cardiovascular events such as heart attack and stroke.
Sera Prognostics has named Sherree Frazier to be VP of sales and marketing. Frazier will head the company's commercial activities, including development and launch of the ProNid diagnostic test to predict preterm birth risk. Frazier formerly was senior director of molecular diagnostics and head of North American clinical sales at Qiagen, and prior to that she was women's health manager at Adeza Biomedical, before it was acquired by Cytyc.
HealthLinx has announced that Stewart Washer and John Chiplin have resigned from its board of non-executive directors. Washer joined HealthLinx's board in 2008 and Chiplin in 2010. The company said it would evaluate whether or not to replace them on the board.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.